斑蝥酸钠维生素B<sub>6</sub>注射液联合TP方案化疗对晚期NSCLC的疗效及相关指标的影响

doi:10.3969/j.issn.1671-7171.2019.02.017

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the therapeutic effect of sodium cantharidate vitamin B₆ combined with paclitaxel and cisplatin chemotherapy (TP) on advanced non-small cell lung cancer (NSCLC) and its influence on tumor markers and angiogenesis.Methods A total of 76 cases of advanced NSCLC patients was randomly divided into two group (n=38) . Patients in the control group were treated with TP chemotherapy only while those in the observation group were treated with sodium cantharidin combined with TP chemotherapy. Patients in both groups completed 2 courses of treatment. The short-term efficacy, serum contents of tumor markers and angiogenesis markers were compared between two groups. Results After 2 courses of treatment, the effective rate (RR) and disease control rate (DCR) in the observation group were higher than those in the control group (P<0.05) and the serum tumor markers Cyfra21-1, (CEA), carbohydrate antigen125 (CA125) and angiogenesis indicators of vascular endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), matrix metalloproteinase-9 were lower than the control group (P<0.05). Conclusion Sodium hyaluronate vitamin 6 combined with TP chemotherapy can improve the treatment effect in patients with advanced NSCLC and reduce angiogenesis activity.

Key words： Carcinoma Non-Small-Cell Lung/ DT Cisplatin/TU

Received: 27 March 2018

PACS:

R730.26

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Da-zhong

Cite this article:

WANG Da-zhong. Efficacy of Sodium Cantharidin Combined with TP Themotherapy on Advanced Non-small Cell Lung Cancer and Influence on Tumor Angiogenesis[J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(2): 265-270.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.02.017 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I2/265

[1] 冯江,陈立军. 培美曲塞或吉西他滨联合卡铂治疗晚期非小细胞肺癌的临床疗效及安全性评价[J]. 中国临床药理学杂志,2015,31(13):1230-1234.
[2] 周韬,王明艳,李文婷,等. 斑蝥酸钠对肝癌细胞SMMC-7721周期、凋亡及端粒酶影响研究[J]. 辽宁中医药大学学报,2014,16(5):29-32.
[3] Xiang T, Kang X, Gong Z, et al. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies[J]. Cancer Chemother Pharmacol, 2017, 79(4): 791-800.
[4] Yoneshima Y, Morita S, Ando M, et al. Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer[J]. Clin Lung Cancer, 2017, 18(1): 100-103.
[5] 黄丹仪,吴转斌,黄勤,等. 斑蝥酸钠与喜树碱联用抗肿瘤效果的实验研究[J]. 中国细胞生物学学报,2014,36(11):1519-1525.
[6] Cao YT, Li JH, Wang YT, et al. Serum ALDH1A1 is a tumor marker for the diagnosis of non-small cell lung cancer[J]. Tumori, 2014, 100(2): 214-218.
[7] 杨德仁,夏伟,马蓉. 非小细胞肺癌手术前后血清肿瘤标志物的监测意义[J]. 中国肿瘤外科杂志,2014,6(1):25-28.
[8] Tomita M, Ayabe T, Chosa E, et al. Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer[J]. Asian Pac J Cancer Prev, 2017, 18(1): 287-291.
[9] 翟乃亮,刘金苹,高福泉. 非小细胞肺癌患者血清中VEGF、Ang-2和survivin的表达及相关性研究[J]. 滨州医学院学报,2016,39(1):23-26.
[10] Mu M, Song Y, Zhang B. Expression and survival significance of B-cell-specific Moloney murine leukemia virus integration site 1 and matrix metalloproteinase-9 in non-small-cell lung cancer[J]. Oncol Lett, 2016, 12(5): 3715-3722.